Effect of Terlipressin on Renal Function in Liver Cirrhosis With Ascites: A Pilot Study.
作者信息
An Yang, Bai Zhaohui, Guo Xiaozhong, Qi Xingshun
机构信息
Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, 110840, PR China.
Postgraduate College, Shenyang Pharmaceutical University, Shenyang, 110840, PR China.
出版信息
J Clin Exp Hepatol. 2020 Nov-Dec;10(6):643-645. doi: 10.1016/j.jceh.2020.05.002. Epub 2020 May 11.
Abstract
摘要
相似文献
1
Effect of Terlipressin on Renal Function in Liver Cirrhosis With Ascites: A Pilot Study.特利加压素对肝硬化腹水患者肾功能的影响：一项初步研究
J Clin Exp Hepatol. 2020 Nov-Dec;10(6):643-645. doi: 10.1016/j.jceh.2020.05.002. Epub 2020 May 11.
2
Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial.多培沙明可逆转特利加压素的心脏抑制作用，但不能改善肝硬化和腹水患者的肾功能：一项随机对照试验。
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G313-G321. doi: 10.1152/ajpgi.00328.2019. Epub 2019 Dec 16.
3
4
Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.特利加压素可改善肝硬化腹水且无肝肾综合征患者的肾功能。
Hepatology. 2007 Dec;46(6):1863-71. doi: 10.1002/hep.21901.
5
Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study.特利加压素对肝硬化腹水患者的全身、门静脉和肾脏影响：初步研究
J Gastroenterol Hepatol. 2004 Jan;19(1):73-7. doi: 10.1111/j.1440-1746.2004.03226.x.
6
Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites.肝硬化和顽固性腹水患者对心房利钠肽与特利加压素联合用药的利钠反应。
J Hepatol. 1997 Jun;26(6):1229-34. doi: 10.1016/s0168-8278(97)80456-4.
7
Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.特利加压素在肝硬化伴腹水且无肝肾综合征患者中的作用：当前证据的系统评价。
Can J Gastroenterol Hepatol. 2020 Jun 22;2020:5106958. doi: 10.1155/2020/5106958. eCollection 2020.
8
[Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].特利加压素治疗顽固性肝硬化腹水的疗效及特点观察
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):982-988. doi: 10.3760/cma.j.issn.1007-3418.2019.12.010.
9
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.特利加压素与白蛋白治疗肝硬化腹腔穿刺术诱发循环功能障碍的随机对照研究
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7. doi: 10.1111/j.1440-1746.2006.04182.x.
10
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.特利加压素联合白蛋白比单独使用白蛋白更能改善肝硬化合并肝肾综合征 1 型患者的肾功能。
Gastroenterology. 2016 Jun;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026. Epub 2016 Feb 16.
引用本文的文献
1
Impact of acute kidney injury on the risk of mortality in patients with cirrhosis: a systematic review and meta-analysis.急性肾损伤对肝硬化患者死亡风险的影响：系统评价和荟萃分析。
Ren Fail. 2022 Dec;44(1):1-14. doi: 10.1080/0886022X.2022.2142137.
本文引用的文献
1
Use of Terlipressin in Cirrhosis With Ascites: A Questionnaire Survey in China.特利加压素在肝硬化腹水患者中的应用：一项中国问卷调查
J Clin Exp Hepatol. 2020 Jul-Aug;10(4):407-408. doi: 10.1016/j.jceh.2019.11.010. Epub 2019 Dec 5.
2
Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding.特利加压素对肝硬化急性上消化道出血患者肾功能的影响。
Ann Transl Med. 2020 Mar;8(6):340. doi: 10.21037/atm.2020.02.135.
3
Development of hyponatremia after terlipressin in cirrhotic patients with acute gastrointestinal bleeding: a retrospective multicenter observational study.特利加压素治疗后肝硬化急性上消化道出血患者低钠血症的发生情况：一项回顾性多中心观察性研究
Expert Opin Drug Saf. 2020 May;19(5):641-647. doi: 10.1080/14740338.2020.1734558. Epub 2020 Feb 26.
4
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.肝性肾病综合征的病理生理学、定义和分类的新进展：超越国际腹水俱乐部（ICA）共识文件的一步。
J Hepatol. 2019 Oct;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11.
5
Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.特利加压素治疗肝肾综合征：当前证据概述。
Curr Med Res Opin. 2019 May;35(5):859-868. doi: 10.1080/03007995.2018.1552575. Epub 2019 Jan 4.
6
Management of ascites and hepatorenal syndrome.腹水和肝肾综合征的管理。
Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23.
7
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.特利加压素治疗1型肝肾综合征的随机、前瞻性、双盲、安慰剂对照试验
Gastroenterology. 2008 May;134(5):1360-8. doi: 10.1053/j.gastro.2008.02.014. Epub 2008 Feb 13.
8
Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features.肝硬化患者的肾衰竭与细菌感染：流行病学及临床特征
Hepatology. 2007 Jan;45(1):223-9. doi: 10.1002/hep.21443.
9
Natural history of patients hospitalized for management of cirrhotic ascites.因肝硬化腹水管理而住院患者的自然病史。
Clin Gastroenterol Hepatol. 2006 Nov;4(11):1385-94. doi: 10.1016/j.cgh.2006.08.007.
10
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.特利加压素与白蛋白治疗肝硬化腹腔穿刺术诱发循环功能障碍的随机对照研究
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7. doi: 10.1111/j.1440-1746.2006.04182.x.
Zotero 插件